Inclusion Criteria:

1. History of breast cancer, lung cancer or melanoma

2. Diagnosis of NM as proven either by: 1. positive CSF cytology, or 2. magnetic
resonance neuro-imaging, or 3. both

3. Age >/=18 years.

4. Routine laboratory studies adequate with bilirubin creatinine <1.0 x ULN, granulocytes >1500, platelets> 75,000; Hb >/= 9.0.

5. Patient able to sign informed consent and willing to participate in study primary
objectives

6. At least 1 week from last intrathecal chemotherapy (>2 weeks if liposomal
cytarabine). Patients are allowed to have received prior chemotherapy for their
tumor. No limit on prior chemotherapies will be made. Patients who have been treated
with tyrosine kinase inhibitors are permitted. Prior anti-VEGF targeted therapy is
not permitted, unless patient has been off anti-VEGF therapy for 6 months and did not
develop NM while on anti-VEGF therapy

7. KPS >/= 50%

8. Pre-treatment CSF Indium 111 CSF flow study without evidence of obstruction.

9. Patients on full-dose anticoagulants (e.g., warfarin) with PT INR >1.5 are eligible
provided that: 1. Patients are receiving anticoagulation (warfarin or low molecular
weight heparins (LMWH)) only if the patients can be off of warfarin for 4-5 days
prior to the LP and placed on LMWH in that interim, and if the 'treatment dose' of
LMWH can be safely held for 24 hours before and after the LP.

10. ( 9. continued) INR must be <1.2 prior to LP in this circumstance. If patients are
receiving thromboprophylaxis dose of LMWH, the patients can be enrolled, but the
thromboprophylaxis LMWH must be able to be safely held for 12 hours prior to the LP.
2. The patient has no active bleeding or pathological condition that carries a high
risk of bleeding 3. There is no evidence of serious or non-healing wound, ulcer or
bone fracture

11. Ventricular reservoir NOT mandatory

Exclusion Criteria:

1. Evidence of active CNS hemorrhage in the brain or tumor lesions

2. Besides NM, other known CNS disease, except for treated brain metastases(Patients
must be at least 1 month out from brain irradiation and have no evidence of
progression or hemorrhage at that time, as ascertained by clinical examination and
brain imaging (MRI or CT) during the screening period). Anticonvulsants (stable dose)
are allowed. Treatment for brain metastases may include whole brain radiotherapy,
radiosurgery or a combination as deemed appropriate by the treating physician.

3. (2. continued) With respect to irradiation for other purpose (for NM or bone
metastases, etc) patients need only 1 week out from the completion of irradiation.
Patients with CNS metastases treated by neurosurgical resection or brain biopsy
performed within 3 months prior to Day 1 will be excluded.

4. Patients with clinically significant cardiovascular disease are excluded 1)
Inadequately controlled HTN (SBP > 140 mmHg and/or DBP > 90 mmHg despite
antihypertensive medication). 2) Prior history of hypertensive crisis or hypertensive
encephalopathy. 3) New York Heart Association (NYHA) Grade II or greater congestive
heart failure.

5. ( 4. Continued) 4) History of myocardial infarction or unstable angina within 6
months prior to Day 1. 5) History of stroke or transient ischemic attack within 6
months prior to Day 1. 6) Significant vascular disease (e.g., aortic aneurysm,
requiring surgical repair or recent peripheral arterial thrombosis) within 6 months
prior to Day 1. 7) Clinically significant peripheral vascular disease. 8) Serious and
inadequately controlled cardiac arrhythmia

6. History of hemoptysis (>/= 1/2 teaspoon of bright red blood per episode) within 1
month prior to Day 1

7. Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)

8. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1 or anticipation of need for major surgical procedure during the course
of the study

9. Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to Day 1. Ventricular reservoir must have been
placed more than 28 days prior to Day 1.

10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Day 1

11. Serious, non-healing wound, active ulcer, or untreated bone fracture

12. Proteinuria as demonstrated by UPC ratio >/=1.0 at screening or by urine dipstick >/=
2+. (Patients discovered to have >/= 2+ proteinuria on urinalysis at baseline should
undergo a 24 hour urine collection and must demonstrate to be eligible).

13. Known hypersensitivity to any component of bevacizumab

14. Intrathoracic or extrathoracic lung carcinoma of squamous cell histology. Mixed
tumors will be categorized by the predominant cell type unless small cell elements
are present, in which case the patient is ineligible; sputum cytology alone is
acceptable.

15. (14. continued) Patients with extrathoracic-only squamous cell NSCLC are eligible.
Patients with only peripheral lung lesions (of any non squamous NSCLC histology,
except small cell histology) will also be eligible (a peripheral lesion is defined as
a lesion in which the epicenter of the tumor is diaphragmatic pleura in a three-dimensional orientation based on each lobe of the
lung and is >/= 2 cm from the trachea, main, and lobar bronchi).

16. Pregnant (positive pregnancy test) or nursing women. Angiogenesis is critical to
fetal development and the inhibition of angiogenesis following administration of
AVASTIN is likely to result in adverse effects on pregnancy. There are no adequate
and well-controlled studies in pregnant women. Both fertile men and women must agree
to use adequate contraceptive measures during study therapy and for at least 2 months
after the completion of bevacizumab therapy.

17. General Medical Exclusions 1) Inability to comply with study and/or follow-up
procedures 2) Life expectancy of less than 6 weeks 3) Current, recent (within 4 weeks
of the first infusion of this study), or planned participation in an experimental
drug study other than this Genentech supported study 4) Active malignancy, other than
superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of
the cervix within the last 5 years